[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615019":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":41,"centralContacts":45,"locations":53,"responsibleParty":353,"collaborators":28,"id":355,"slug":28,"hasResults":356,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":356,"sex":362,"minAge":363,"maxAge":28,"enrollmentInfo":364,"targetDuration":28,"studyType":367,"phases":368,"briefSummary":370,"conditions":371,"keywords":28,"overallStatus":56,"whyStopped":28,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":382},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1","EXPERIMENTAL","Participants will receive Inavolisib plus enzalutamide",[13,14],"Drug: Inavolisib","Drug: Enzalutamide",{"label":16,"type":17,"description":18,"interventionNames":19},"Arm 2","ACTIVE_COMPARATOR","Participants will receive either ARPi switch (enzalutamide or abiraterone) or docetaxel",[14,20,21],"Drug: Abiraterone","Drug: Docetaxel",[23,29,33,37],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Inavolisib","Inavolisib will be administered orally as per the schedule specified in the protocol.",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"Enzalutamide","Enzalutamide will be administered orally as per the schedule specified in the protocol.",[9,16],{"type":24,"name":34,"description":35,"armGroupLabels":36,"otherNames":28},"Abiraterone","Abiraterone will be administered orally as per the schedule specified in the protocol.",[16],{"type":24,"name":38,"description":39,"armGroupLabels":40,"otherNames":28},"Docetaxel","Docetaxel will be administered intravenously as per the schedule specified in the protocol.",[16],[42],{"name":43,"affiliation":5,"role":44},"Clinical Trials","STUDY_DIRECTOR",[46,51],{"name":47,"role":48,"phone":49,"phoneExt":28,"email":50},"Reference Study ID Number: CO45813 https:\u002F\u002Fforpatients.roche.com\u002F","CONTACT","888-662-6728 (U.S. and Canada)","global-roche-genentech-trials@gene.com",{"name":52,"role":48,"phone":28,"phoneExt":28,"email":28},"Fastest response: use the inquiry form. No email attachments. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[54,67,77,87,97,107,118,128,137,147,158,168,177,185,196,206,212,223,232,243,254,263,269,275,281,292,301,310,320,324,333,342],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":28},"UCSF","RECRUITING","San Francisco","California","94115","United States",{"type":62,"coordinates":63},"Point",[64,65],-122.41942,37.77493,{"lat":65,"lon":64},{"facility":68,"status":56,"city":69,"state":70,"zip":71,"country":60,"cosmosGeoPoint":72,"geoPoint":76,"contacts":28},"Holden Comprehensive Cancer Center","Iowa City","Iowa","52242-1009",{"type":62,"coordinates":73},[74,75],-91.53017,41.66113,{"lat":75,"lon":74},{"facility":78,"status":56,"city":79,"state":80,"zip":81,"country":60,"cosmosGeoPoint":82,"geoPoint":86,"contacts":28},"Montefiore Einstein Cancer Center","The Bronx","New York","10461",{"type":62,"coordinates":83},[84,85],-73.86641,40.84985,{"lat":85,"lon":84},{"facility":88,"status":56,"city":89,"state":90,"zip":91,"country":60,"cosmosGeoPoint":92,"geoPoint":96,"contacts":28},"Lifespan Cancer Institute","Providence","Rhode Island","02903-4923",{"type":62,"coordinates":93},[94,95],-71.41283,41.82399,{"lat":95,"lon":94},{"facility":98,"status":56,"city":99,"state":100,"zip":101,"country":60,"cosmosGeoPoint":102,"geoPoint":106,"contacts":28},"Carolina Urologic Research Center","Myrtle Beach","South Carolina","29572-4607",{"type":62,"coordinates":103},[104,105],-78.88669,33.68906,{"lat":105,"lon":104},{"facility":108,"status":56,"city":109,"state":110,"zip":111,"country":112,"cosmosGeoPoint":113,"geoPoint":117,"contacts":28},"Royal North Shore Hospital-Pacific Hwy","St Leonards","New South Wales","2065","Australia",{"type":62,"coordinates":114},[115,116],151.19836,-33.82344,{"lat":116,"lon":115},{"facility":119,"status":56,"city":120,"state":121,"zip":122,"country":112,"cosmosGeoPoint":123,"geoPoint":127,"contacts":28},"Sunshine Coast University Hospital","Birtinya","Queensland","4575",{"type":62,"coordinates":124},[125,126],153.11913,-26.74322,{"lat":126,"lon":125},{"facility":129,"status":56,"city":130,"state":121,"zip":131,"country":112,"cosmosGeoPoint":132,"geoPoint":136,"contacts":28},"Royal Brisbane & Womens Hospital","Herston","4006",{"type":62,"coordinates":133},[134,135],153.01852,-27.44453,{"lat":135,"lon":134},{"facility":138,"status":56,"city":139,"state":140,"zip":141,"country":112,"cosmosGeoPoint":142,"geoPoint":146,"contacts":28},"Box Hill Hospital","Box Hill","Victoria","3128",{"type":62,"coordinates":143},[144,145],145.12545,-37.81887,{"lat":145,"lon":144},{"facility":148,"status":56,"city":149,"state":150,"zip":151,"country":152,"cosmosGeoPoint":153,"geoPoint":157,"contacts":28},"Irmandade Da Santa Casa de Misericordia de Porto Alegre","Porto Alegre","Rio Grande do Sul","90035-074","Brazil",{"type":62,"coordinates":154},[155,156],-51.23019,-30.03283,{"lat":156,"lon":155},{"facility":159,"status":56,"city":160,"state":161,"zip":162,"country":152,"cosmosGeoPoint":163,"geoPoint":167,"contacts":28},"CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia","Santo André","São Paulo","09060-650",{"type":62,"coordinates":164},[165,166],-46.53833,-23.66389,{"lat":166,"lon":165},{"facility":169,"status":56,"city":170,"state":161,"zip":171,"country":152,"cosmosGeoPoint":172,"geoPoint":176,"contacts":28},"Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS","São José do Rio Preto","15090-000",{"type":62,"coordinates":173},[174,175],-49.37944,-20.81972,{"lat":175,"lon":174},{"facility":178,"status":56,"city":161,"state":28,"zip":179,"country":152,"cosmosGeoPoint":180,"geoPoint":184,"contacts":28},"Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira - ICESP","01246-000",{"type":62,"coordinates":181},[182,183],-46.63611,-23.5475,{"lat":183,"lon":182},{"facility":186,"status":56,"city":187,"state":188,"zip":189,"country":190,"cosmosGeoPoint":191,"geoPoint":195,"contacts":28},"Princess Margaret Cancer Centre","Toronto","Ontario","M5G 2M9","Canada",{"type":62,"coordinates":192},[193,194],-79.39864,43.70643,{"lat":194,"lon":193},{"facility":197,"status":56,"city":198,"state":199,"zip":200,"country":190,"cosmosGeoPoint":201,"geoPoint":205,"contacts":28},"Centre de recherche du Centre Hospitalier de l'Universite de Montreal","Montreal","Quebec","H2X 0A9",{"type":62,"coordinates":202},[203,204],-73.58781,45.50884,{"lat":204,"lon":203},{"facility":207,"status":56,"city":198,"state":199,"zip":208,"country":190,"cosmosGeoPoint":209,"geoPoint":211,"contacts":28},"Jewish General Hospital","H3T 1E2",{"type":62,"coordinates":210},[203,204],{"lat":204,"lon":203},{"facility":213,"status":56,"city":214,"state":215,"zip":216,"country":217,"cosmosGeoPoint":218,"geoPoint":222,"contacts":28},"EDOG - Institut Bergonie - PPDS","Bordeaux","Gironde","33000","France",{"type":62,"coordinates":219},[220,221],-0.58046,44.84124,{"lat":221,"lon":220},{"facility":224,"status":56,"city":225,"state":28,"zip":226,"country":217,"cosmosGeoPoint":227,"geoPoint":231,"contacts":28},"Centre Léon Bérard","Lyon","69008",{"type":62,"coordinates":228},[229,230],4.84789,45.74906,{"lat":230,"lon":229},{"facility":233,"status":56,"city":234,"state":235,"zip":236,"country":237,"cosmosGeoPoint":238,"geoPoint":242,"contacts":28},"Istituti Fisioterapici Ospitalieri","Rome","Lazio","00144","Italy",{"type":62,"coordinates":239},[240,241],12.51133,41.89193,{"lat":241,"lon":240},{"facility":244,"status":56,"city":245,"state":246,"zip":247,"country":248,"cosmosGeoPoint":249,"geoPoint":253,"contacts":28},"Seoul National University Bundang Hospital","Seongnam-si","Gyeonggido","13620","South Korea",{"type":62,"coordinates":250},[251,252],127.13778,37.43861,{"lat":252,"lon":251},{"facility":255,"status":56,"city":256,"state":28,"zip":257,"country":248,"cosmosGeoPoint":258,"geoPoint":262,"contacts":28},"Seoul National University Hospital","Seoul","03080",{"type":62,"coordinates":259},[260,261],126.9784,37.566,{"lat":261,"lon":260},{"facility":264,"status":56,"city":256,"state":28,"zip":265,"country":248,"cosmosGeoPoint":266,"geoPoint":268,"contacts":28},"Severance Hospital, Yonsei University Health System","03722",{"type":62,"coordinates":267},[260,261],{"lat":261,"lon":260},{"facility":270,"status":56,"city":256,"state":28,"zip":271,"country":248,"cosmosGeoPoint":272,"geoPoint":274,"contacts":28},"Asan Medical Center.","05505",{"type":62,"coordinates":273},[260,261],{"lat":261,"lon":260},{"facility":276,"status":56,"city":256,"state":28,"zip":277,"country":248,"cosmosGeoPoint":278,"geoPoint":280,"contacts":28},"Samsung Medical Center","06351",{"type":62,"coordinates":279},[260,261],{"lat":261,"lon":260},{"facility":282,"status":56,"city":283,"state":284,"zip":285,"country":286,"cosmosGeoPoint":287,"geoPoint":291,"contacts":28},"Hospital Universitario Cruces","Barakaldo","Vizcaya","48903","Spain",{"type":62,"coordinates":288},[289,290],-2.98813,43.29639,{"lat":290,"lon":289},{"facility":293,"status":56,"city":294,"state":28,"zip":295,"country":286,"cosmosGeoPoint":296,"geoPoint":300,"contacts":28},"C.H. Regional Reina Sofia - PPDS","Córdoba","14004",{"type":62,"coordinates":297},[298,299],-4.77275,37.89155,{"lat":299,"lon":298},{"facility":302,"status":56,"city":303,"state":28,"zip":304,"country":286,"cosmosGeoPoint":305,"geoPoint":309,"contacts":28},"Hospital Universitario 12 de Octubre","Madrid","28041",{"type":62,"coordinates":306},[307,308],-3.70256,40.4165,{"lat":308,"lon":307},{"facility":311,"status":56,"city":312,"state":28,"zip":313,"country":314,"cosmosGeoPoint":315,"geoPoint":319,"contacts":28},"Ankara Universitesi Tip Fakultesi Hastaneleri - Cebeci Hastanesi","Ankara","6590","Turkey (Türkiye)",{"type":62,"coordinates":316},[317,318],32.85427,39.91987,{"lat":318,"lon":317},{"facility":321,"status":56,"city":322,"state":28,"zip":323,"country":314,"cosmosGeoPoint":28,"geoPoint":28,"contacts":28},"VM Medical Park Samsun Hastanesi","Atakum","55200",{"facility":325,"status":56,"city":326,"state":28,"zip":327,"country":314,"cosmosGeoPoint":328,"geoPoint":332,"contacts":28},"Koc Universitesi Hastanesi","Istanbul","41380",{"type":62,"coordinates":329},[330,331],28.94966,41.01384,{"lat":331,"lon":330},{"facility":334,"status":56,"city":335,"state":28,"zip":336,"country":314,"cosmosGeoPoint":337,"geoPoint":341,"contacts":28},"Izmir Medical Point Hospital","Izmir","35101",{"type":62,"coordinates":338},[339,340],27.13838,38.41273,{"lat":340,"lon":339},{"facility":343,"status":56,"city":344,"state":345,"zip":346,"country":347,"cosmosGeoPoint":348,"geoPoint":352,"contacts":28},"The Royal Marsden in Sutton, Surrey - Downs Rd","Sutton","Surrey","SM2 5PT","United Kingdom",{"type":62,"coordinates":349},[350,351],-0.2,51.35,{"lat":351,"lon":350},{"type":354,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100615019",false,"NCT07287150","A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer","A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer","InavoPC","Inclusion Criteria:\n\n* Histologically or cytologically confirmed adenocarcinoma of the prostate without small-cell or neuroendocrine features\n* Progressive metastatic CRPC, defined as any of the following: PSA progression, defined by a minimum of two rising PSA values from three consecutive assessments with an interval of at least 7 days between assessments and with a minimal starting value of PSA \\>=1 ng\u002FmL; The most recent qualifying PSA value must be determined within 14 days of enrollment; Soft tissue disease progression, defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1); Bone disease progression, defined by PCWG3 criteria, with two or more new metastatic bone lesions on a whole-body radionuclide bone scan\n* Treatment with at least one, but no more than one, prior second-generation ARPi (abiraterone, apalutamide, enzalutamide, darolutamide) for hormone- sensitive prostate cancer (HSPC) or CRPC\n* Availability of a tumor tissue specimen that is suitable (e.g., adequate quality and quantity) for use in determining biomarker status\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Fasting glucose \\\u003C100 mg\u002FdL and HbA1c \\\u003C 5.7%\n\nExclusion Criteria:\n\n* Presence of liver metastasis\n* Prior treatment with any phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKT), or mammalian target of rapamycin (mTOR) inhibitor, or with any agent with a mechanism of action of inhibiting the PI3K\u002FAKT\u002FmTOR pathway\n* Type 1 or Type 2 diabetes mellitus\n* Prior treatment for mCRPC with cytotoxic chemotherapy or novel hormonal treatments (e.g., androgen receptor degraders, CYP11 inhibitors), with the following treatments permitted: Prior docetaxel in mHSPC, providing no evidence of disease progression occurred during treatment or within 6 months of treatment completion; Prior docetaxel in the adjuvant or neoadjuvant setting providing no evidence of disease progression occurred during treatment or within 12 months of treatment completion; Prior treatment with sipuleucel-T, with the last dose administered \\>28 days prior to start of treatment; Prior PARPi therapy, as per local prescribing information, with the last dose administered \\>14 days prior to start of treatment; One prior RLT or radiotherapeutic agent (e.g., PSMA-targeted RLT, Radium 223) with the last dose administered \\>8 weeks prior to start of treatment\n* Other concurrent anti-cancer therapy except for androgen deprivation therapy\n* Treatment with strong CYP2C8 inhibitors, strong or moderate CYP2C8 inducers, or strong CYP3A4 inducers within 1 week or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study treatment\n* Transfusion of any blood product for the sole purpose of making a potential participant eligible for study inclusion or within 28 days of enrollment","MALE","18 Years",{"count":365,"type":366},100,"ESTIMATED","INTERVENTIONAL",[369],"PHASE2","This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.",[372],"Metastatic Castration-Resistant Prostate Cancer","2026-06-03",{"date":375,"type":376},"2026-06-04","ACTUAL",{"date":378,"type":376},"2026-03-11",{"date":380,"type":366},"2029-07-30",{"name":5,"class":6},32]